Podcasts about Follicular lymphoma

Featuring perspectives from Dr Stephen M Ansell and Dr Brian T Hill, including the following topics: Introduction: Bispecific Antibodies in Community Practice (0:00) Diffuse Large B-Cell Lymphoma (7:06) CD19, CD20 or Both? AZD0486 Bispecific Antibody (29:15) Mantle Cell Lymphoma (32:36) Follicular Lymphoma (48:08) CAR T-Cell Therapy for Marginal Zone Lymphoma (57:17) CME information and select publications

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: EZH2 Inhibitors for Follicular Lymphoma (FL) (0:00) Bruton Tyrosine Kinase Inhibitors for FL (5:43) Anti-CD19 Antibodies for FL (9:40) Other Novel Agents Under Clinical Development for FL (18:50) Case: A woman in her early 80s with multiple comorbidities and relapsed FL (23:06) Case: A man in his early 40s with high-risk progressive FL that did not achieve deep remission with prior therapy (27:07) Case: A woman in her early 70s with rheumatoid arthritis and relapsed FL (33:46) CME information and select publications

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.

This week, we kick off a new series, this time focusing on follicular lymphoma! This series will build on a lot of fundamentals that we discussed in our prior series. In this first episode, we start with an introduction to how to approach management of this disease.Episode contents:- What is the best approach to biopsy? - What is the differential for CD10+ cells on flow? - How is follicular lymphoma classified? - What is the workup for a new suspected FL? **** Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Follicular Lymphoma (FL) (0:00) Case: A man in his late 60s with relapsed FL who received axicabtagene ciloleucel (axi-cel) but experienced cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and chronic cytopenia (3:50) Published Clinical Data Involving Axi-cel (10:24) Case: A man in his mid 60s with multiple comorbidities and progressive FL who received tisagenlecleucel (tis-cel) (15:34) Published Clinical Data Involving Tis-cel (19:47) Case: A woman in her late 40s with multiple comorbidities and refractory FL who received lisocabtagene maraleucel (liso-cel) after prior mosunetuzumab (22:43) Published Clinical Data Involving Liso-cel (26:05) Incidence and Management of Toxicities Associated with CAR T-Cell Therapy (27:48) Sequencing Considerations and Ongoing Trials Involving CAR T-Cell Therapy (30:35) Practical Considerations and Referrals for CAR T-Cell Therapy Administration (31:59) CME information and select publications

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.

- Overview of Follicular Lymphoma - Treatment Options for Newly Diagnosed - Treatment Options for Relapsed/Refractory Disease - Clinical Trial Updates: How Research Increases Treatment Options - New & Emerging Treatments - Factors that May Affect Treatment Planning - Side Effect Prevention & Management - Tips to Improve Communicating with the Health Care Team - The Importance of Health Care Communication - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Quality-of-Life Concerns & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team - Practical & Psychosocial Support to Cope with Follicular Lymphoma - Questions for Our Panel of Experts

- Overview of Follicular Lymphoma - Treatment Options for Newly Diagnosed - Treatment Options for Relapsed/Refractory Disease - Clinical Trial Updates: How Research Increases Treatment Options - New & Emerging Treatments - Factors that May Affect Treatment Planning - Side Effect Prevention & Management - Tips to Improve Communicating with the Health Care Team - The Importance of Health Care Communication - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Quality-of-Life Concerns & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team - Practical & Psychosocial Support to Cope with Follicular Lymphoma - Questions for Our Panel of Experts

- Overview of Follicular Lymphoma - Treatment Options for Newly Diagnosed - Treatment Options for Relapsed/Refractory Disease - Clinical Trial Updates: How Research Increases Treatment Options - New & Emerging Treatments - Factors that May Affect Treatment Planning - Side Effect Prevention & Management - Tips to Improve Communicating with the Health Care Team - The Importance of Health Care Communication - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions, Quality-of-Life Concerns & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team - Practical & Psychosocial Support to Cope with Follicular Lymphoma - Questions for Our Panel of Experts

Dr Michael Northend (University College London Hospitals NHS Foundation Trust, and Cancer Research UK & UCL Cancer Trials Centre, London, UK) joins us to discuss the long-term results of a randomised, phase 3 trial on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00034-1/fulltext?dgcid=buzzsprout_icw_podcast_28-04-25_lanhaeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Featuring a slide presentation from Dr Matthew Matasar and related discussion from Dr Carla Casulo, Dr Matasar and Dr Laurie H Sehn, including the following topics: Overview of Bispecific Antibodies for the Treatment of Relapsed/Refractory (R/R) Follicular Lymphoma (FL) (0:00) Clinical Data Available with Mosunetuzumab for R/R FL (1:54) Clinical Data Available with Epcoritamab for R/R FL (4:54) Clinical Data Available with Odronextamab for R/R FL (6:53) Clinical Considerations in Selecting Among Available Bispecific Antibodies for R/R FL (8:34) Practical Considerations in the Administration of Bispecific Antibodies (15:21) The Role of Vaccinations in the Prevention of Infections for Patients Receiving Bispecific Antibodies (18:34) Ongoing Clinical Trials Evaluating Bispecific Antibodies for FL (21:34) Case: A man in his late 60s with refractory FL who received mosunetuzumab monotherapy (24:24) Case: A woman in her late 50s with relapsed FL who received third-line epcoritamab monotherapy (30:14) Case: A man in his late 80s with a long-standing history of FL who received odronextamab in combination with a second novel bispecific antibody (33:48) CME information and select publications

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, Dr Matthew Matasar from Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Laurie H Sehn from BC Cancer Centre for Lymphoid Cancer in Vancouver discuss recent updates on available and novel treatment strategies for relapsed/refractory follicular lymphoma. CME information and select publications here.

CME credits: 0.25 Valid until: 15-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/chairperson-perspective-core-concepts-for-community-based-practice-the-evolving-role-of-bispecific-antibody-therapy-in-relapsed-or-refractory-follicular-lymphoma/29191/ Dr. Tycel Phillips presents a summary and offers expert insights on relevant and timely advances in bispecific antibody therapy for the treatment of R/R FL. The activity reviews topics including differentiating approved bispecific antibodies, evidence- and guideline-based treatment planning, patient selection, practical considerations, and optimizing safety in the application of bispecific antibody therapy in R/R FL.=

In this week's episode we'll find out about longer term results from a pivotal trial of mosunetuzumab in relapsed/refractory follicular lymphoma, potential use of CD70 CAR T-cells that secrete an anti-CD33/anti-CD3 bispecific antibody as a therapy for acute myeloid leukemia, and how ferroptosis regulates hemolysis in stored red blood cells.Featured Articles:Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapiesCD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AMLFerroptosis regulates hemolysis in stored murine and human red blood cells

Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17) Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46) Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44) CME information and select publications  

Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCART24).

In this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed: 1. 3 RCTs in Mantle Cell Lymphoma: a) Update on TRIANGLE: https://ash.confex.com/ash/2024/webprogram/Paper200735.htmlb) ENRICT Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP or BR]): https://ash.confex.com/ash/2024/webprogram/Paper199710.htmlc) ECOG-ACRIN EA4151 Trial (Auto-HCT vs Rituximab maintenance alone in patients with undetectable MRD after induction): https://ash.confex.com/ash/2024/webprogram/Paper212973.html2. DLBCL: a) Update on POLARIX Trial: https://ash.confex.com/ash/2024/webprogram/Paper197938.htmlb) Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in DLBCL Patients Receiving Polatuzumab Vedotin: https://ash.confex.com/ash/2024/webprogram/Paper202153.htmlc) COALITION trial: https://ash.confex.com/ash/2024/webprogram/Paper204930.html3. Follicular Lymphoma: a) Phase 3 inMIND trial (Tafasitamab + R2 vs Placebo + R2): https://ash.confex.com/ash/2024/webprogram/Paper212970.htmlb) Loncastuximab tesirine with rituximab in patients with R/R FL: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00345-4/abstract4. CLL: a) AMPLIFY Trial (Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy in 1st line CLL): https://ash.confex.com/ash/2024/webprogram/Paper200701.html5. Hodgkin Lymphoma: a) Pembrolizumab Maintenance Instead of Auto-HCT for R/R HL: https://ash.confex.com/ash/2024/webprogram/Paper202537.html

Discover key updates on emerging immunotherapy combinations in relapsed/refractory (R/R) follicular lymphoma (FL) from the hematology congress in San Diego. Credit available for this activity expires: 12/18/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002061?ecd=bdc_podcast_libsyn_mscpedu

In this week's episode, unravelling follicular lymphoma subtypes. Researchers dissect the biological diversity of follicular lymphoma and introduce a new prognostic mode, that could change the way this B-cell neoplasm is subtyped and treated. Then, concerning stroke rate trends in sickle cell disease. A new report shows increasing rates of cerebrovascular events among people with SCD in California. Finally, procoagulant platelet activation promotes venous thrombosis. Investigators report finding procoagulant platelets in the circulation and in thrombi of patients and mice with DVT or PE. Featured Articles:Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significanceRates of strokes in Californians with sickle cell disease in the post-STOP eraProcoagulant platelet activation promotes venous thrombosis

Dr Gilles Salles from the Memorial Sloan Kettering Cancer Center in New York, New York, reviews current and novel EZH1/2 inhibitor-based treatment strategies for follicular lymphoma, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/WCWtK2024/EZH2Lymphoma).

Welcome to OncLive On Air®! I'm your host today, Ashling Wahner.  OncLive On Air  is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.  In today's episode, supported by AbbVie, we had the pleasure of speaking with Jennifer Crombie, MD, about the FDA approval of epcoritamab-bysp (Epkinly) for patients with relapsed/refractory follicular lymphoma. Dr Crombie is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School in Boston, Massachusetts. On June 26, 2024, the FDA granted accelerated approval to epcoritamab for the treatment of adult patients with relapsed/refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy. This regulatory decision was supported by findings form the phase 1/2 EPCORE NHL-1 trial (NCT03625037), in which the agent yielded an overall response rate of 82% (95% CI, 74.1%-88.2%) in the primary efficacy cohort (n = 127), including a complete response rate of 60% (95% CI, 50.8%-68.4%).  In our exclusive interview, Dr Crombie discussed the significance of this approval, key findings from the pivotal EPCORE NHL-1 trial, and where the future of the FL treatment paradigm is headed.  ___ That's all we have for today! Thank you for listening to this episode of OncLive On Air, supported by AbbVie. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.  For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.  OncLive is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.  If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!  Thanks again for listening to OncLive On Air.  *OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn. 

In this episode, we speak with Susete Ferreira, a Toronto-based cancer warrior originally from Portugal. Susete shares her incredible journey from initially mistaking cancer symptoms for menopause to being diagnosed with stage 4 follicular lymphoma, a type of blood cancer. Despite the intense pain and challenges, Susete's positivity and resilience shine through as she discusses how she turned to social media to connect with others, finding strength in an online community. She offers invaluable advice on maintaining a positive outlook and emphasizes the importance of listening to your body and seeking medical attention when something feels off. Join us for an inspiring conversation filled with hope, strength, and practical wisdom for those facing their own cancer journeys. Immortalize your voice by being an ALL TALK ONCOLOGY GUEST! Just fill-out this FORM. FREE WEBINAR: https://www.alltalkoncology.com/webinar HELPFUL LINKS: If you want to seek our help, join our "I Have Cancer, Am I Going To Die?" program. Cancer Mindset Mini-Course: "It Starts With Your Mind". 5 Stage Of Winning Against My Cancer Diagnosis E-Book. Claim your Digital Copy Now! SOCIAL MEDIA LINKS: All Talk Oncology: Instagram & Facebook Your Cancer Guy: Instagram WEBSITES: https://www.alltalkoncology.com https://www.yourcancerguy.com

Featuring perspectives from Dr Joshua Brody, Dr Ian W Flinn and Dr Tycel Phillips, including the following topics: Introduction: CD3 Bispecific Antibodies in the Community Oncology Setting (0:00) Integration of Bispecific Antibody Therapy into the Management of Diffuse Large B-Cell Lymphoma — Dr Phillips (18:13) Current and Future Role of Bispecific Antibodies in Follicular Lymphoma and Other B-Cell Lymphomas — Dr Flinn (41:20) Tolerability and Other Practical Considerations with the Use of Bispecific Antibody Therapy — Dr Brody(50:49) CME information and select publications

Tycel Phillips, MD, spoke with CancerNetwork® ahead of the FDA's accelerated approval of epcoritamab-bysp (Epkinly) for patients with relapsed/refractory follicular lymphoma to discuss how this agent may impact the treatment paradigm. Phillips, an associate professor in the Division of Lymphoma and Department of Hematology & Hematopoietic Stem Cell Transplantation at City of Hope in Duarte, California, reviewed data from the phase 1/2 EPCORE NHL-1 trial (NCT03625037), which ultimately supported the approval of epcoritamab in the aforementioned population. Topline results reported at the time of the agent's approval showed an overall response rate (ORR) of 82% (95% CI, 74.1%-88.2%), with 60% of patients experiencing a complete response. Additionally, the median duration of response was not reached (NR; 95% CI, 13.7-NR).  Beyond the supporting data, Phillips highlighted how this approval may increase availability of treatment options for patients with follicular lymphoma, especially those who lack access to alternative therapies. He stated that readily available off-the-shelf bispecific antibodies like epcoritamab may bridge the gap for patients who are unable to access CAR T-cell therapies or travel to a major academic center for treatment.  Phillips also detailed strategies for mitigating some of the common toxicities that may occur following treatment with epcoritamab, which include cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Although Phillips said that epcoritamab is usable in the third-line setting, he noted that bispecific antibodies like it “have a lot of potential for upward mobility,” as he anticipates further assessment of these treatments in the first or second line. “As community oncologists get more and more comfortable with these drugs and have the structure to set up to safely administer [them] for the first month when most of the complications happen, more and more patients will be able to be treated, which will be a great benefit based on what we've seen in early response rates for these drugs,” Phillips said regarding the utility of bispecific antibodies like epcoritamab. “There'll be a big benefit for the patient population in the long term as more community settings implement these drugs into their clinical practice.” Reference FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory follicular lymphoma. News release. FDA. June 26, 2024. Accessed June 26, 2024. https://tinyurl.com/26s9myey

Featuring perspectives from Dr John N Allan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, including the following topics: Introduction (0:00) First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) (11:44) The Impact of Comorbid Conditions on the Choice of First-Line Therapy for Newly Diagnosed CLL (18:08) Toxicities and Other Practical Considerations with Venetoclax-Based Treatment (25:17) The Selection and Sequencing of Therapies for Relapsed/Refractory CLL (35:45) The Tolerability of Available Bruton Tyrosine Kinase (BTK) Inhibitors (40:43) The Potential Role of Therapy Combining BTK Inhibitors and Venetoclax (48:48) Bispecific Antibodies as a Treatment Option for Non-Hodgkin Lymphoma (1:04:19) Cytokine Release Syndrome and Neurotoxicity with Bispecific Antibodies (1:06:25) Other Tolerability and Toxicity Issues with Bispecific Antibody Therapy (1:10:44) Bispecific Antibodies for the Management of Follicular Lymphoma (1:18:19) The Role of Bispecific Antibody Therapy in the Treatment of Diffuse Large B-Cell Lymphoma (1:24:17) Other Practical Considerations with the Use of Bispecific Antibodies (1:40:59) NCPD information and select publications

Could tattoos be a risk factor for malignant lymphoma? Find out about this and more in today's PeerDirect Medical News Podcast.

 | Join us for an insightful episode with Dr. Kieran Dunleavy, an internationally recognized expert in lymphoma and blood cancers. Learn about the innovative treatments and clinical trials happening at Medstar Georgetown University Hospital that are transforming patient care. Discover how accurate diagnosis and cutting-edge therapies like CAR T cells and bispecific antibodies are improving outcomes and reducing toxicity. Don't miss this opportunity to stay informed about the future of cancer treatment. Listen now! For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

Featuring perspectives from Dr Andrew D Zelenetz, including the following topics: Follicular Lymphoma (0:00) Mantle Cell Lymphoma (30:29) Diffuse Large B-Cell Lymphoma (55:01) Hodgkin Lymphoma (1:12:25) CME information and select publications

Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostConf24/Lymphoma).

In this week's episode, we'll discuss the findings from a study assessing responses after treatment with tisagenlecleucel [LM1] in adults with relapsed/refractory follicular lymphoma, learn more about the association between high microRNA-145 plasma levels and decreased risk of future incident venous thromboembolism, and discuss how epigenetic and immunogenetic signatures can be used in the prediction of outcomes for high-count monoclonal B lymphocytosis.Featured Articles: Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update Prediction of outcomes for high-count monoclonal B lymphocytosis using an epigenetic and immunogenetic signature High microRNA-145 plasma levels are associated with decreased risk of future incident venous thromboembolism: The HUNT study 

- Overview of Follicular Lymphoma - Treatment Options for Newly Diagnosed - Treatment Options for Relapsed/Refractory Disease - Clinical Trial Updates - How Research Contributes to Treatment Options - New & Emerging Treatments - Factors that May Affect Treatment Planning - Side Effect Prevention & Management - Tips to Improve Communicating with the Health Care Team - The Importance of Communication - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team - Practical & Psychosocial Support to Cope with Follicular Lymphoma - Questions for Our Panel of Experts

- Overview of Follicular Lymphoma - Treatment Options for Newly Diagnosed - Treatment Options for Relapsed/Refractory Disease - Clinical Trial Updates - How Research Contributes to Treatment Options - New & Emerging Treatments - Factors that May Affect Treatment Planning - Side Effect Prevention & Management - Tips to Improve Communicating with the Health Care Team - The Importance of Communication - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team - Practical & Psychosocial Support to Cope with Follicular Lymphoma - Questions for Our Panel of Experts

- Overview of Follicular Lymphoma - Treatment Options for Newly Diagnosed - Treatment Options for Relapsed/Refractory Disease - Clinical Trial Updates - How Research Contributes to Treatment Options - New & Emerging Treatments - Factors that May Affect Treatment Planning - Side Effect Prevention & Management - Tips to Improve Communicating with the Health Care Team - The Importance of Communication - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team - Practical & Psychosocial Support to Cope with Follicular Lymphoma - Questions for Our Panel of Experts

Visit nascentmc.com/podcast for full show notes Visit learnamastyle.com for the free course on ChatGPT4 for medical writers and editors.  - The FDA has approved amivantamab (Rybrevant) in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test. This approval converts the May 2021 accelerated approval of amivantamab to full approval. - The FDA approved the AGENT Drug-Coated Balloon (DCB) for treating in-stent restenosis in coronary artery disease patients, introducing the first drug-coated coronary balloon in the US. It uses a paclitaxel-coated catheter to deliver medication directly to the vessel wall, offering an alternative to traditional treatments and aiming to reduce recurrence risks. The approval was based on the AGENT IDE trial, demonstrating its effectiveness over uncoated balloon angioplasty in reducing lesion failure, with no significant adverse events reported. - The FDA approved an oral suspension form of ibrutinib (Imbruvica) for several conditions, including chronic lymphocytic leukemia and chronic graft versus host disease, addressing the needs of patients who have difficulty swallowing pills. This is the first oral suspension formulation of a Bruton's tyrosine kinase inhibitor, originally approved in 2013 for mantle cell lymphoma. The approval, granted to Johnson & Johnson and Pharmacyclics, aims to simplify treatment for patients challenged with pill-swallowing. - Epcoritamab-bysp (Epkinly) received FDA approval for treating adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies, marking it as the first subcutaneously administered bispecific antibody for this condition. It works by targeting both CD3 on T cells and CD20 on B cells to induce cell death. Based on the EPCORE NHL-1 trial results, this approval extends its use beyond diffuse large B-cell lymphoma, with AbbVie and Genmab sharing commercial responsibilities.  - The FDA granted priority review to the New Drug Application for govorestat (AT-007), a treatment for classic galactosemia, potentially the first of its kind if approved. Govorestat, an aldose reductase inhibitor, aims to reduce harmful galactitol levels, based on phase 3 study results among pediatric patients. Applied Therapeutics announced a PDUFA target action date of August 28, 2024, highlighting the urgent need for treatments in this area. - Obeticholic acid (Ocaliva) received FDA consideration for an expanded application to treat primary biliary cholangitis, building on its 2016 accelerated approval. It's designed for patients with or without cirrhosis, showing promise in post-marketing studies to confirm its clinical benefits. The review includes data from various studies and real-world evidence, with a PDUFA target date of October 15, 2024, aiming to address the needs of this autoimmune liver disease population.  - The FDA approved Biktarvy for HIV patients with suppressed viral loads who exhibit M184V/I resistance, offering a new treatment option for those with specific resistance mutations. Biktarvy combines three therapies in a single tablet, based on successful 48-week study data. Manufactured by Gilead Sciences, this approval expands treatment possibilities for patients facing resistance challenges. - The FDA rejected Minerva Neurosciences' New Drug Application for roluperidone as a treatment for schizophrenia's negative symptoms, citing insufficient evidence from a single study and lack of comprehensive data. Despite showing promise in targeting specific brain receptors, the FDA's concerns highlight the need for more extensive research and data to confirm its effectiveness and safety. Minerva plans to engage with the FDA to address these issues.

Please visit answersincme.com/XHR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in follicular lymphoma discuss the integration of bispecific antibodies into the treatment of relapsing/refractory follicular lymphoma. Upon completion of this activity, participants should be better able to: Review the clinical profiles of novel CD20 x CD3 bispecific antibodies (BsAbs) for relapsing/refractory follicular lymphoma (R/R FL); Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL; and Outline evidence-based multidisciplinary strategies for optimal integration of BsAbs in the treatment plans of patients with R/R FL.

Please visit answersincme.com/NRW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the optimization of care for patients with relapsed/refractory follicular lymphoma (R/R FL) and treatment with bispecific antibodies (BsAbs). Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BsAbs in patients with R/R FL; Review the clinical profiles of novel anti-CD20 × CD3 BsAbs for R/R FL; and Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL.

Please visit answersincme.com/NRW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the optimization of care for patients with relapsed/refractory follicular lymphoma (R/R FL) and treatment with bispecific antibodies (BsAbs). Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BsAbs in patients with R/R FL; Review the clinical profiles of novel anti-CD20 × CD3 BsAbs for R/R FL; and Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL.

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024 Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

This is an accredited continuing education series of three (3) podcasts as downloadable audio files (MP3). During this podcast series, Gilles Salles, MD, and Matthew Lunning, MD, identify and integrate crucial advances in follicular lymphoma presented at the 2023 American Society of Hematology (ASH) annual conference.Launch Date: February 1, 2024Release Date: February 1, 2024Expiration Date: January 31, 2025FACULTY BIOSGilles Salles, MDChief, Lymphoma ServiceMemorial Sloan Kettering Cancer CenterMatthew Lunning, DOAssociate Professor of Hematology/OncologyUniversity of Nebraska Medical CenterThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/conversations-in-hematologyoncology-incorporating-key-updates-in-the-treatment-of-follicular-lymphoma-a-discussion-following-ash-2023-on-assimilating-practice-changing-breakthroughs-14

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more!

This week's episode will be focusing on one of the Non-Hodgkin Lymphomas: Follicular Lymphoma. We will go over the important details on diagnostic criteria, indications for treatment and treatment options.

Dr Lunning sits down with Caron A. Jacobson, MD, MMSc, or Dana-Farber Cancer Institute, to discuss the characteristics of FL that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.

Featuring perspectives from Prof Mitesh J Borad, Dr Anthony El-Khoueiry, Dr Christopher R Flowers, Dr Sara A Hurvitz, Dr Thomas E Hutson, Dr Amrita Krishnan, Dr Ann S LaCasce, Dr Heather McArthur, Dr Bradley J Monk, Dr Kathleen N Moore, Dr Robert Z Orlowski and Dr Guru P Sonpavde, moderated by Dr Neil Love, co-moderated by Dr Stephen “Fred” Divers, including the following topics: Introduction (0:00) Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma — Ann S LaCasce, MD, MMSc (8:26) Follicular Lymphoma and Mantle Cell Lymphoma — Christopher R Flowers, MD, MS (42:55) CME information and select publications

Drs Lunning and Nastoupil discuss the ins and outs of diagnostic workups for patients with follicular lymphoma; how to discern which patients may benefit most from standard chemotherapy vs clinical trial regimens in the frontline setting; and ongoing follicular lymphoma research that may alter the treatment paradigm.

Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayBispecificNHL23)

Featuring perspectives from Professor Martin Hutchings and Dr Loretta J Nastoupil, including the following topics: Introduction (0:00) Follicular Lymphoma (2:42) Diffuse Large B-Cell Lymphoma (35:41) CME information and select publications

Dr Ian W Flinn discusses the management of Hodgkin and non-Hodgkin lymphoma. CME information and select publications here (http://www.researchtopractice.com/MTPLymphoma23/)

Sue Doty from Michigan thought she had a hip problem when she went to stand up one day and collapsed, but the doctors diagnosed her with follicular lymphoma—a type of blood cancer that's not usually curable. She then underwent 6 rounds of chemo but quit when the cancer had spread to her lungs and bones and made her unbearably sick. Instead, she began taking cannabis oil, which her husband made for her. She is now celebrating being 11 years cancer free.